RNA, U1 small nuclear 58, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-58P profile across patient tissues and cancer cell-line models. RNU1-58P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNU1-58P is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, RNU1-58P RNA expression shows 7,233 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, COAD, and TGCT as cancer lineages where RNU1-58P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-58P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-58P survival associations across molecular data types. RNU1-58P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-58P RNA expression–survival associations across cancer types. High RNU1-58P expression shows unfavorable associations in KIRC, ESCA, UCS, ACC and BLCA, but favorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RNU1-58P RNA expression.
This table summarizes RNU1-58P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-58P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-58P shows higher tumor expression in COAD. The COAD box plot shows higher RNU1-58P RNA expression in tumor versus normal tissue (log2 FC = +1.670, t-test p = .029).
This table shows molecular features associated with RNU1-58P in patient tissues and cancer cell lines. In patient samples, RNU1-58P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
